Company / Shareholders' Equity
Terns Pharmaceuticals, Inc. Shareholders' Equity History
FY2020-FY2024 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Shareholders' Equity
$345.9M
FY2024
5-year range
-$117.4M / $345.9M
FY2020-FY2024
Trend
+35.4%
vs FY2023
Sector context
#121 of 214
Health Care
What the data says
At $346M, Terns Pharmaceuticals, Inc.'s shareholders' equity ranks #121 of 214 in the Health Care sector. Improved from $277M to $346M over the past 2 years.
Based on SEC 10-K filings.
$346M in FY2024 with a 3-year CAGR of +29.2%.
Improved from $277M to $346M over the past 2 years.
Health Care sector context is included.
Shareholders' Equity over time
Growth rates
- 3-Year CAGR
- +29.2%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#121 of 214 in Health CareTop 57% of 214This company $345.9M Sector average $2.6B
▼
-86.5% below sector average
Key checks
Key Insights
- 3-year CAGR of +29.2%, indicating consistent growth.
- In FY2024, shareholders' equity increased 35.4% year-over-year.
- Ranks #121 out of 214 companies in the Health Care sector.
- Lowest shareholders' equity in the period was in FY2020.
Company context
Key Data Points
- Altman Z-Score 7.86 (safe zone, above 2.9 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Shareholders' EquityValue | YoY GrowthYoY |
|---|---|---|
| FY2024 | $345.9M | +35.4% |
| FY2023 | $255.4M | -7.8% |
| FY2022 | $276.9M | +72.8% |
| FY2021 | $160.3M | +236.5% |
| FY2020 | -$117.4M | - |
As of FY2024 · SEC 10-K · Updated Feb 28, 2026